OTHER INFORMATION
−Removed: During the quarter ended March 31,
−Removed: 2025, no Director or Officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1
−Removed: trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
+Added: During the quarter ended June 30, 2025, no Director
+Added: or Officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,”
+Added: as each term is defined in Item 408(a) of Regulation S-K.
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *
5 unchanged sentences
Furnished herewith.
−Removed: Pursuant to the requirements of the Securities Exchange
−Removed: Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized, on May
+Added: Pursuant to the requirements of the Securities
+Added: Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized,
+Added: on August 12, 2025.
SUNSHINE BIOPHARMA INC.
4 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.